% 0期刊文章%尼古拉斯异常终止伊万·桑切斯费尔南德斯% % Satish Agadi % Sookee一个% Ravindra Arya %一个凯文·查普曼杰西卡木匠% %威廉•盖拉德%一个格劳瑟特蕾西%霍华德Goodkin %穆罕默德米卡提%卡特里娜Peariso %一个玛吉令他Ramgopal % % Tobias Loddenkemper % T在难治性惊厥的临床特点和治疗策略在儿童癫痫持续状态:小儿癫痫持续状态研究小组的结果(pSERG) (P03.012) % D J神经病学2013% % P P03.012-P03.012 % V 80% N % X 7补充目的:描述难治性惊厥的临床特点及治疗方法的癫痫持续状态(RCSE)的孩子。首页背景:没有足够的儿科RCSE文献不同的治疗方案。设计/方法:我们进行了前瞻性多中心研究,儿童入学RCSE来自7个不同的参考医院在美国从2011年6月到2012年9月,包容性。我们包括所有患者:1)癫痫持续状态(SE)惊厥的发作,2)30天至21岁,和3)耐火材料,至少两种不同的抗癫痫药物(aed)(苯二氮卓类不是管理作为一个连续输液是一种药物),或要求至少一个连续注入aed。结果:40例(23男性)年龄在0.2到17.7之间(中间值:2.6)年满足我们的入选标准。在发作,CSE连续(35%)或间歇性的发作没有回到基线(60%)。基本医疗条件发育迟缓(42.5%)、癫痫(37.5%),前一集的SE(20%)和脑瘫(7.5%)。SE的病因是结构(22.5%)、代谢(12.5%)、遗传(7.5%)和未知的(57.5%)。中位数(四分位范围)时间在几分钟内从癫痫发作:1)首先aed 17.5(5 - 65.3) 2)第一卢是60(30 - 112.5),3)第二卢是96(75.5 - -322.5),和4)剧烈癫痫持续状态是120年底(71.3 -207)。aed的:1)第一:氯羟去甲安定(40.4%)、安定(19.2%)、咪达唑仑(11.5%);2)第一个卢:fosphenytoin(38.5%)、苯妥英(17.3%)、levetiracetam(5.8%)、苯巴比妥(3.8%)、丙戊酸钠(1.9%);3)第二个卢:苯巴比妥(34.6%)、fosphenytoin (9.6%)、levetiracetam(9.6%)、苯妥英(3.8%)、丙戊酸钠(3.8%)。 Continuous infusions were used in 14 patients: midazolam (12), pentobarbital (1), and propofol (1). Three patients required a second infusion with midazolam (2) and pentobarbital (1).CONCLUSIONS: In our series, RCSE was more frequently intermittent, and of undetermined etiology. Although AEDs used followed published guidelines, the period between administration of benzodiazepines and non-benzodiazepines was prolonged.Supported by: Epilepsy Foundation of America.Disclosure: Dr. Sánchez Fernández has nothing to disclose. Dr. Abend has nothing to disclose. Dr. Agadi has nothing to disclose. Dr. An has nothing to disclose. Dr. Arya has nothing to disclose. Dr. Carpenter has nothing to disclose. Dr. Chapman has nothing to disclose. Dr. Gaillard has received personal compensation for activities with King Pharmaceutical as a participant on an advisory board. Dr. Gaillard has received research support from Questcor. Dr. Glauser has received personal compensation for activities with Questcor Pharmaceuticals, Inc., Lundbeck Research USA, Sunovion, Supernus Pharmaceuticals, Eisai, Inc., and Upsher-Smith Laboratories as a consultant and/or speaker. Dr. Glauser has received patent payments from AssureRx. Dr. Goodkin has nothing to disclose. Dr. Mikati has nothing to disclose. Dr. Peariso has nothing to disclose. Dr. Ramgopal has nothing to disclose. Dr. Ream has nothing to disclose. Dr. Loddenkemper has received personal compensation in an editorial capacity for European Journal of Epilepsy. Dr. Loddenkemper has received research support from the National Institutes of Health/NINDS, Harvard Medical School and Boston Children's Hospital.Tuesday, March 19 2013, 2:00 pm-6:30 pm %U